Press Releases

Prevent Blindness Declares Third Annual Geographic Atrophy Awareness Week

Prevent Blindness provides free geographic atrophy educational resources for patients, care partners and healthcare professionals.

Published

5 months ago

December 1, 2023

Press Releases

(PRESS RELEASE) CHICAGO – Prevent Blindness, the nation’s leading nonprofit eye health organization, is announcing the third annual Geographic Atrophy (GA) Awareness Week as Dec. 4-10, 2023. GA is a medical term that refers to later-stage cases of dry age-related macular degeneration (AMD). Macular degeneration is an eye condition that affects the macula of the retina. More than 8 million people in the world have GA, with an estimated 1 million in the United States, according to the Cleveland Clinic.

Prevent Blindness offers a variety of free, educational resources on GA including a dedicated webpage, expert videos, a comprehensive fact sheetand a series of social media graphics. The fact sheet and graphics are available in English and Spanish. This year’s GA Awareness Week is supported by funding from Apellis Pharmaceuticals, Inc., and Iveric Bio, an Astellas Company.

Additionally, Prevent Blindness is participating in the first World Geographic Atrophy Day on Tuesday, Dec. 5, 2023. The goal of the new initiative is to empower the voices of the global GA community, and provide education, advocacy, and support. World Geographic Atrophy Day is a partnership between BrightFocus Foundation, Fighting Blindness Canada, Macular Society, and Prevent Blindness, and is supported with funding provided by Apellis Pharmaceuticals, Inc.

As part of GA Week at Prevent Blindness, a new episode in the Prevent Blindness Focus on Eye Health Expert Series, “Advancements in Treatments for Geographic Atrophy,” will be available featuring Rajeev S. Ramchandran, MD, MBA, Associate Professor of Ophthalmology, Flaum Eye Institute, University of Rochester Medical Center. Dr. Ramchandran also serves as the volunteer chairperson of the Prevent Blindness Scientific Committee, and is a member of its Board of Directors.

Additional Focus on Eye Health Expert Series episodes include “Geographic Atrophy and Patient Support,” featuring Prevent Blindness Ohio Past president and CEO, Sherry Williams, sharing her story as a care partner for her mother diagnosed with GA, and the “Geographic Atrophy” episode, with Janet S. Sunness, MD, medical director of the Richard E. Hoover Low Vision Rehabilitation Services at the Greater Baltimore Medical Center.

GA can lead to progressive and permanent vision loss. Patients with GA in one eye are more likely to develop it in the other eye. There may be no symptoms in the early stages until the disease progresses or affects both eyes. Vision changes due to GA may include some of the following symptoms:

Difficulty seeing in the center of vision
Numbers or letters disappearing or missing when reading
A dim or dark spot in central or near central (side) vision
Trouble seeing in dim light
Needing extra light to read
Dull or washed-out colors
Vision not as clear or sharp

“The good news is that promising new treatments for GA are now available, with additional options in development,” said Jeff Todd, president and CEO of Prevent Blindness. “By working closely with their eye doctors, people with GA have hope to preserve their vision from the damaging effects of GA.”

For GA and/or AMD patients and their care partners, Prevent Blindness also offers the free resource, Living Well With Low Vision. This program provides a variety of free directories, a library of self-help guides, downloadable apps including “GuideME for AMD,” access to clinical trial research, and recentAMD research news.

For more information on geographic atrophy, please visit here. For a listing of vision care financial assistance programs in English or Spanish, visit here.

click to Comment(Comment)

Up Next

HelpMeSee Wins NTSA Modeling and Simulation Award

Don't Miss

ReFocus Eye Health Expands Its Partner Network in DC, PA, NJ, and CT

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width³ according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion⁴ and seamless transitions from near to far.

For more information, visit here.